 IRVINE, CA, Sept. 22, 2021 GLOBE NEWSWIRE -- Odyssey Group International, Inc. OTC: ODYY the Company or Odyssey, a medical company focused on developing unique, life-saving medical products, today announced successful completion of their clinical trial site initiation visit and the start of subject screening and enrollment. The drug candidate PRV-002 is being developed to treat concussion as a novel neurosteroid delivered nasally. Odysseys Phase 1 clinical trial status can be viewed at 